ewing sarcoma epidemiology forecast

Key Highlights

• Ewing’s sarcoma is relatively uncommon in those older than 20 and most common in those between the ages of 5 and 20.
• More than 80% of incident cases were observed in those under 18 years old and only 20% were found in adults.
• Ewing sarcoma is more common in males than in females. Data suggests that nearly two-thirds of people with Ewing sarcoma are males, and one-third are females.
• The prognosis for Ewing sarcoma has improved over the years due to advances in treatment. The 5-year survival rate for localized Ewing sarcoma is around 70–80%, while the survival rate for metastatic disease is lower, around 30–40%. However, it is important to note that survival rates can vary depending on individual factors and the response to treatment.

DelveInsight’s “Ewing Sarcoma – Epidemiology – 2034” report delivers an in-depth understanding of Ewing Sarcoma, historical and forecasted epidemiology of Ewing Sarcoma in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Ewing Sarcoma Disease Understanding

Ewing Sarcoma Overview

Ewing Sarcoma

Ewing sarcoma (also known as Ewing’s sarcoma) is a cancerous tumor that usually begins growing in a bone. It occurs primarily in children and young adults, often appearing during the teen years. Although Ewing’s sarcoma can develop in any bone, it usually affects the long bones, such as the thighbone (femur), shinbone (tibia), and upper arm bone (humerus). The bones of the pelvis are also often affected. Occasionally, the tumor begins in the muscles and soft tissues. The most common symptoms are stiffness, pain, swelling, or tenderness in the bone or the tissue surrounding the bone.

Ewing Sarcoma Diagnosis

The patient’s journey begins with symptoms such as persistent bone pain even at rest, swelling, and a large palpable mass on the affected bone. Followed by a visit to the orthopedist, where the patient is suggested diagnostic tests such as MRI, CT scan, and plain radiography. After the diagnosis, the patient is referred to an oncologist for further treatment, and a tissue biopsy is performed of the mass removed from the most aggressive portion of the cancer as determined by imaging for confirmatory diagnosis. Once Ewing Sarcoma is confirmed, relevant treatment is given to the patient.

Further details related to diagnosis are provided in the report…

Ewing Sarcoma Epidemiology

As the market is derived using a patient-based model, the Ewing Sarcoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of Ewing Sarcoma, gender-specific cases of Ewing Sarcoma, age-specific cases of Ewing Sarcoma, stage-specific cases of Ewing Sarcoma in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034. The total incident cases of Ewing sarcoma in the 7MM comprised approximately 1,250 cases in 2022 and are projected to increase during the forecast period.

• In the 7MM, the highest incident cases of  Ewing Sarcoma were seen in the United States, followed by EU4 and the UK.
• Among EU4, Germany accounted for the highest number of Ewing sarcoma cases, followed by France, whereas Italy accounted for the lowest cases.
• In age-specific cases of Ewing sarcoma in 2022, the maximum number of cases were observed in 10–14 years of age group.
• Males than females are more likely to get Ewing Sarcoma. In the United States in 2022, ~300 incident cases of male Ewing Sarcoma were found.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts contacted for insights on Ewing Sarcoma evolving treatment landscape, patient reliance on conventional therapies, patient’s therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers; Medical Oncologists; Orthopedists, and Professors; MD, FACS, Chair of the Department of Orthopedic Surgery, and professor at UC Davis Comprehensive Cancer Center in Sacramento, California; MD, Director, Sarcoma Oncology Center, California; and others.

Delveinsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as MD Anderson Cancer Center, Sarcoma Oncology Center, Cancer Research UK Barts Centre in London, MD Anderson Cancer Center, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Ewing Sarcoma market trends.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Ewing Sarcoma, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journey in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Ewing Sarcoma Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Age-wise cases of Ewing Sarcoma

Ewing Sarcoma Report Key Strengths

• Ten Years Forecast
• 7MM Coverage
• Ewing Sarcoma Epidemiology Segmentation

Ewing Sarcoma Report Assessment

• Current Diagnostic Practices
• Unmet Needs

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Ewing Sarcoma? What will be the growth opportunities across the 7MM concerning the patient population with Ewing Sarcoma?
• What is the historical and forecasted Ewing Sarcoma patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• How many Ewing Sarcoma patients are diagnosed with localized or metastatic disease?
• Which gender has a higher incidence of Ewing Sarcoma?
• Which age group of Ewing Sarcoma has a high patient share?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the age-specific Ewing Sarcoma incidence cases in varying geographies over the coming years.
• A detailed overview of stage-specific and gender-specific cases of Ewing Sarcoma is an inclusion.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent and treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.